http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

tamiflu is an influenza neuraminidase inhibitor indicated for treatment of influenza in patients 1 year and older who have been symptomatic for no more than 2 days 1 1 prophylaxis of influenza in patients 1 year and older 1 2 important limitations of use efficacy not established in patients who begin therapy after 48 hours of symptoms 1 3 not a substitute for annual influenza vaccination 1 3 no evidence of efficacy for illness from agents other than influenza viruses types a and b 1 3 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 3 tamiflu is indicated for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days tamiflu is indicated for the prophylaxis of influenza in patients 1 year and older the following points should be considered before initiating treatment or prophylaxis with tamiflu efficacy of tamiflu in patients who begin treatment after 48 hours of symptoms has not been established tamiflu is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices there is no evidence for efficacy of tamiflu in any illness caused by agents other than influenza viruses types a and b influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use tamiflu

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_8469 DOID_8469

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00198 drugbank:DB00198

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-12T14:44:56.782Z

http://purl.org/np/RAyIryxwdj... RAyIryxwdj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-12T14:44:56.782Z